Tandem Diabetes Care (TNDM) Return on Capital Employed (2014 - 2026)

Tandem Diabetes Care has reported Return on Capital Employed for 13 years, with the latest figure at 10.89% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 1626.0% year-over-year to 10.89%; the trailing twelve-month figure through Mar 2026 stood at 10.89% (up 1626.0% YoY), and the FY2025 full-year result was 27.47%, down 1357.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 10.89%, up from 29.48% in the prior quarter.
• The five-year high for Return on Capital Employed was 1.27% in Q1 2022, with the low at 31.5% in Q3 2025.
• Historically, Return on Capital Employed has averaged 19.64% across 5 years, with a median of 19.9% in 2024.
• Annual changes were most pronounced in 2023 — Return on Capital Employed slumped 2909 bps — and 2024, when it surged 1720 bps.
• Tandem Diabetes Care's Return on Capital Employed stood at 10.49% in 2022, then plunged by 196 bps to 31.05% in 2023, then soared by 55 bps to 13.85% in 2024, then tumbled by 113 bps to 29.48% in 2025, then surged by 63 bps to 10.89% in 2026.
• The last three Return on Capital Employed figures came in at 10.89% (Q1 2026), 29.48% (Q4 2025), and 31.5% (Q3 2025), per Business Quant data.